Richter's syndrome
Not recruitingStudy on the Safety and Effectiveness of Venetoclax, Atezolizumab, and Obinutuzumab for Patients with Richter Syndrome from Chronic Lymphocytic Leukemia
Study on the Safety and Effectiveness of Venetoclax, Atezolizumab, and Obinutuzumab for Patients with Richter Syndrome from Chronic Lymphocytic Leukemia
- Disease:Richter's syndrome
- Substances:AtezolizumabObinutuzumab+1
Italy- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:ASST Grande Ospedale Metropolitano Niguarda









